Integrated Computational Strategies for identifying Potential Drug Candidates against Spinal Tuberculosis
Abstract
Drug resistance against various diseases including tuberculosis (TB) is an unfortunate reality of humankind. Total drug resistance (TDR) against TB has been a major cause of increasing cases throughout the world. Moreover, finding a new drug is more challenging against such a disease. Herein, we have selected a drug target SLC11A1 (Solute carrier 11 protein), which is a divalent cation transporter and is crucial for uptake of important ions in the bacterial cytosol. The targeting of SLC11A1 through novel inhibitors gives us a putative edge in the direction of drug designing against TB. Therefore, we have screened a library of bioactive compounds from a commercial database and identified a few of them based on virtual screening scores and their interactions with the potential binding site. Further, these compounds were investigated using Molecular dynamics (MD) simulations for their binding stability. Our findings suggest that repurposed FDA-approved drugs may serve as viable candidates for combating drug-resistant tuberculosis, warranting further experimental validation.